ConvaTec Group (LON:CTEC – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Financial Group in a note issued to investors on Friday,London Stock Exchange reports. They currently have a GBX 325 target price on the stock. Jefferies Financial Group’s target price indicates a potential upside of 55.80% from the company’s current price.
Several other equities research analysts have also commented on the company. Stifel Nicolaus restated a “buy” rating and set a GBX 315 price target on shares of ConvaTec Group in a research note on Wednesday, March 11th. Berenberg Bank reiterated a “buy” rating and set a GBX 340 target price on shares of ConvaTec Group in a report on Tuesday, April 21st. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 315 target price on shares of ConvaTec Group in a research report on Wednesday, April 8th. Finally, Citigroup restated an “outperform” rating and issued a GBX 315 price target on shares of ConvaTec Group in a report on Thursday, March 5th. Nine equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of GBX 319.67.
Read Our Latest Stock Report on ConvaTec Group
ConvaTec Group Trading Down 0.3%
Insider Transactions at ConvaTec Group
In other ConvaTec Group news, insider Jonny Mason sold 291,149 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of GBX 234, for a total value of £681,288.66. Corporate insiders own 0.95% of the company’s stock.
About ConvaTec Group
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
See Also
- Five stocks we like better than ConvaTec Group
- 3 AI Data Center Stocks Worth Watching for Capital Rotation
- McDonald’s Is the Cheapest It’s Been in Years—Does That Make It a Buy?
- Karman: Defense Darling’s Outlook Strengthens After 40% Drop
- Aeluma’s Post-Earnings Dip Creates a Buying Opportunity
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.
